An open label, multicenter, phase II study of KRT-232, an oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel cell carcinoma (MCC) who have failed treatment with anti-PD-1/L1 immunotherapy.

Glenn J. Hanna,James A. DeCaprio,John Hai Ming Mei,Jesse McGreivy

An open label, multicenter, phase II study of KRT-232, an oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel cell carcinoma (MCC) who have failed treatment with anti-PD-1/L1 immunotherapy.

2019

Glenn J. Hanna
James A. DeCaprio
John Hai Ming Mei
Jesse McGreivy

TPS9602Background: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer with a poor prognosis in patients with advanced disease, with mortality as high as 46%. An oncogenic Merke...

Keywords:

Cancer research
Merkel cell carcinoma
Immunotherapy
Phases of clinical research
Small molecule
Pathology
Medicine
Mdm2
anti pd 1
Skin cancer
open label

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations